Experience
Gracell Biotechnologies Agrees to Acquisition by AstraZeneca for up to $1.2 Billion
December 26, 2023
Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, on its definitive agreement to be acquired by AstraZeneca.
Related contacts
Related Practices & Industries
Carmot Therapeutics Enters Definitive Merger Agreement With Roche
December 3, 2023
Cooley advised Carmot Therapeutics, a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, on its definitive merger agreement in which Roche will acquire Carmot.
Related contacts
Related Practices & Industries
Bridge to Life Sells Certain Assets to TransMedics
August 3, 2023
Cooley advised Bridge to Life, an organ preservation and perfusion technologies supplier, on its sale of certain assets – including its EVOSS heart and lung and LifeCradle heart perfusion assets – to TransMedics.
Related contacts
Related Practices & Industries
Travere Sells Bile Acid Product Portfolio to Mirum
July 18, 2023
Cooley advised Travere Therapeutics, a biopharmaceutical company, on its definitive agreement to sell its bile acid product portfolio to Mirum Pharmaceuticals.
Related contacts
Related Practices & Industries
Morphimmune Announces Merger With Immunome and $125 Million Private Investment
July 5, 2023
Cooley advised Morphimmune, a private biotechnology company, in its definitive merger agreement with Immunome and $125 million private investment.
Related contacts
Related Practices & Industries
Admissions & credentials
California